Molecular regulation of neuroinflammation in glaucoma: Current knowledge and the ongoing search for new treatment targets.
AI Summary
This review highlights that glial cell neuroinflammation significantly drives glaucoma's retinal ganglion cell damage. Targeting this inflammation offers a broad, multi-target treatment strategy to protect vision.
Abstract
Neuroinflammation relying on the inflammatory responses of glial cells has emerged as an impactful component of the multifactorial etiology of neurodegeneration in glaucoma. It has become increasingly evident that despite early adaptive and reparative features of glial responses, prolonged reactivity of the resident glia, along with the peripheral immune cells, create widespread toxicity to retinal ganglion cell (RGC) axons, somas, and synapses. As much as the synchronized responses of astrocytes and microglia to glaucoma-related stress or neuron injury, their bi-directional interactions are critical to build and amplify neuroinflammation and to dictate the neurodegenerative outcome. Although distinct molecular programs regulate somatic and axonal degeneration in glaucoma, inhibition of neurodegenerative inflammation can provide a broadly beneficial treatment strategy to rescue RGC integrity and function. Since inflammatory toxicity and mitochondrial dysfunction are converging etiological paths that can boost each other and feed into a vicious cycle, anti-inflammatory treatments may also offer a multi-target potential. This review presents an overview of the current knowledge on neuroinflammation in glaucoma with particular emphasis on the cell-intrinsic and cell-extrinsic factors involved in the reciprocal regulation of glial responses, the interdependence between inflammatory and mitochondrial routes of neurodegeneration, and the research aspects inspiring for prospective immunomodulatory treatments. With the advent of powerful technologies, ongoing research on molecular and functional characteristics of glial responses is expected to accumulate more comprehensive and complementary information and to rapidly move the field forward to safe and effective modulation of the glial pro-inflammatory activities, while restoring or augmenting the glial immune-regulatory and neurosupport functions.
MeSH Terms
Shields Classification
Key Concepts5
Neuroinflammation, driven by inflammatory responses of glial cells, is a significant component in the multifactorial etiology of neurodegeneration in glaucoma.
Prolonged reactivity of resident glia and peripheral immune cells contributes to widespread toxicity to retinal ganglion cell (RGC) axons, somas, and synapses in glaucoma.
Bi-directional interactions between astrocytes and microglia are critical for building and amplifying neuroinflammation and dictating neurodegenerative outcomes in glaucoma.
Inhibition of neurodegenerative inflammation may provide a broadly beneficial treatment strategy to rescue retinal ganglion cell (RGC) integrity and function in glaucoma.
Anti-inflammatory treatments may offer multi-target potential in glaucoma due to the converging etiological paths of inflammatory toxicity and mitochondrial dysfunction, which can boost each other in a vicious cycle.
Related Articles5
Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
Cross-Sectional StudyPhysiological approaches to neuroprotection. boosting of protective autoimmunity.
Basic SciencePotential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration.
ReviewPossible role for memantine in protecting retinal ganglion cells from glaucomatous damage.
Basic ScienceIschemic optic neuropathy and giant cell arteritis.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.